Sotorasib (AMG 510) indication scope and analysis of patients with KRAS mutations

Sotorasib (trade name: Lumakras) is the first oral small molecule inhibitor approved to target the KRAS G12C mutation. KRAS mutation is one of the most common driver genes in a variety of malignant tumors, among which G12C mutations account for about KRAS mutations13% and are more common in non-small cell lung cancer (NSCLC), colorectal cancer and some pancreatic cancers. The approval of sotoracib provides a new treatment option for the KRAS mutation population who have long lacked effective targeted drugs.

Currently, sotoracib is mainly suitable for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who still have KRAS G12C mutations after receiving at least one systemic treatment. In clinical trials, such patients showed significant tumor response when treated with sotoraxib. According to the CodeBreaK 100 study data, patients with KRAS G12CmutationsNSCLC who have received multiple lines of treatment in the past, sotorasib The objective response rate (ORR) is approximately 37%, and the median progression-free survival (PFS) is 6.8 months, bringing substantial clinical benefit to patients.

In addition to NSCLC, sotorasiib is also undergoing clinical studies in patients with KRAS G12C mutated colorectal cancer and pancreatic cancer. Although single-agent efficacy is relatively limited in colorectal cancer, combination anti-EGFR therapies (such as with cetuximab) have shown higher response and disease control rates. At present, multiple clinical trials of combination therapy are advancing, and the application scope of sotoraxib in other KRAS mutated tumors is expected to be expanded in the future.

Overall, the emergence of sotorasiib marks that the "undruggable" geneKRAS has finally been successfully conquered, bringing new hope for survival to patients with related mutations. Although drug resistance remains a challenge, with new combination strategies and second-generationWith the development of KRAS inhibitors, sotoraxib is expected to continue to expand its indications in clinical applications and further improve the long-term prognosis of KRAS mutation patients.

Reference materials:https://www.drugs.com/